| Composition | Sitagliptin 50mg |
|---|---|
| Dosage | TABLET |
| Packing Size | 10×7 |
| Packing | Blister |
SITAPRIME 50 is an oral antidiabetic medication containing Sitagliptin 50 mg, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor designed to help control blood glucose levels in type 2 diabetes mellitus.
By enhancing incretin hormone activity, Sitagliptin increases insulin secretion in response to meals and reduces glucagon levels, promoting stable blood sugar levels throughout the day.
SITAPRIME 50 is ideal for patients who require postprandial glucose management, either as monotherapy or in combination with other antidiabetic agents.
Each tablet contains:
Sitagliptin 50 mg – DPP-4 inhibitor that regulates blood glucose by enhancing insulin secretion and suppressing glucagon.
(Excipients q.s., as per approved formulation.)
Tablet
Oral Antidiabetic / DPP-4 Inhibitor
SITAPRIME 50 Tablets are indicated for:
Type 2 diabetes mellitus in adults
Patients inadequately controlled with diet and exercise alone
As monotherapy or in combination with other antidiabetic medications such as Metformin, Sulfonylureas, or Insulin
Managing postprandial hyperglycemia
Sitagliptin inhibits the DPP-4 enzyme, prolonging the activity of incretin hormones (GLP-1 and GIP).
This leads to increased insulin secretion after meals and reduced glucagon release, resulting in improved postprandial and fasting blood glucose control.
Recommended Dose: 50 mg once daily, with or without food, or as prescribed by the physician
Route: Oral
Duration: As per medical guidance, based on glycemic control and patient response
Note: Regular blood glucose monitoring is recommended during therapy.
Controls fasting and postprandial blood sugar levels
Improves overall glycemic control in type 2 diabetes
Can be used as monotherapy or combination therapy
Low risk of hypoglycemia when used alone
Helps reduce the risk of complications associated with uncontrolled blood sugar
SITAPRIME 50 is generally well tolerated. Possible mild or rare side effects include:
Nasopharyngitis or upper respiratory infection
Headache
Mild gastrointestinal disturbances
Rare hypoglycemia when combined with other antidiabetic drugs
Patients should report persistent side effects to their healthcare provider.
Not suitable for type 1 diabetes mellitus or diabetic ketoacidosis
Dose adjustment may be needed in renal impairment
Monitor for pancreatitis symptoms (abdominal pain, nausea, vomiting)
Inform the physician about other medications to avoid interactions
Consult a doctor before use during pregnancy or lactation
Store below 25°C, in a dry place away from sunlight. Keep out of reach of children.
Brand Name: SITAPRIME 50
Composition: Sitagliptin 50 mg
Dosage Form: Tablet
Therapeutic Class: Oral Antidiabetic / DPP-4 Inhibitor
Manufacturer: [Insert Company Name]
Packaging: [Example: 10×10 Tablets / Strip]
Effective DPP-4 inhibitor therapy for type 2 diabetes
Helps maintain stable blood sugar levels
Suitable for monotherapy or combination therapy
Convenient once-daily dosing
Manufactured under strict GMP standards
SITAPRIME 50 (Sitagliptin 50 mg Tablets) provides effective glycemic control by enhancing insulin secretion and regulating glucagon release. Its once-daily dosing and low risk of hypoglycemia make it an ideal choice for type 2 diabetes patients seeking better postprandial and fasting blood sugar management.
